Erratum: Pluripotent stem cell miRNAs and metastasis in invasive breast cancer (Journal of the National Cancer Institute (2014) 106:12 (dju324) DOI: 10.1093/jnci/dju324);Pluripotent stem cell miRNAs and metastasis in invasive breast cancer

Journal of the National Cancer Institute

Volumn 106, Issue 12, 2014, Pages

  Volinia, Stefano ^a,b   Nuovo, Gerard ^a   Drusco, Alessandra ^a   Costinean, Stefan ^a   Abujarour, Ramzey ^c   Desponts, Caroline ^d   Garofalo, Michela ^a   Baffa, Raffaele ^e   Aeqilan, Rami ^a   Maharry, Kati ^a   Garzon, Maria Elena Sana Ramiro ^a,b   Di Leva, Gianpiero ^a   Gasparini, Pierluigi ^a   Dama, Paola ^a   Marchesini, Jlenia ^b   Galasso, Marco ^b   Manfrini, Marco ^b   Zerbinati, Carlotta ^b   Corrà, Fabio ^b   Wise, Timothy ^a   Wojcik, Sylwia E ^a   Previati, Maurizio ^b   Pichiorri, Flavia ^a   Zanesi, Nicola ^a   Alder, Hansjuerg ^a   Palatini, Jeff ^b   Huebner, Kay F ^a   Shapiro, Charles L ^a   Negrini, Massimo ^b   Vecchione, Andrea ^f   Rosenberg, Anne L ^g   Croce, Carlo M ^a   more..

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF FERRARA   (Italy)

^c Fate Therapeutics   (United States)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

^e THOMAS JEFFERSON UNIVERSITY   (United States)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

^g THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BMI1 PROTEIN; HERMES ANTIGEN; MICRORNA; MICRORNA 203; MICRORNA 302; UNCLASSIFIED DRUG; MIRN302 MICRORNA, HUMAN;

ADULT; ANIMAL CELL; ARTICLE; BIOINFORMATICS; BREAST CARCINOMA; CANCER SURVIVAL; CELL DIFFERENTIATION; CONTROLLED STUDY; DISTANT METASTASIS; EMBRYO; EMBRYONIC STEM CELL; FEMALE; GENE EXPRESSION; GENE REPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN SITU HYBRIDIZATION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; MIDDLE AGED; MOUSE; NEXT GENERATION SEQUENCING; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PLURIPOTENT STEM CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SURVIVAL TIME; BREAST; BREAST TUMOR; CANCER STEM CELL; GENETICS; PAGET NIPPLE DISEASE; PATHOLOGY; SECONDARY;

BREAST; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; LYMPHATIC METASTASIS; MICRORNAS; NEOPLASTIC STEM CELLS; PLURIPOTENT STEM CELLS;

EID: 84922391474     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju373     Document Type: Erratum

References (38)

1. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 2008;8(10):755-768.
2. Clevers H. The cancer stem cell: premises, promises and challenges. Nat Med. 2011;17(3):313-319.
3. Chiang AC, Massague J. Molecular basis of metastasis. N Engl J Med. 2008;359(26):2814-2823.
4. Pece S, Tosoni D, Confalonieri S, et al. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell. 2010;140(1):62-73.
5. Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133(4):704-715.
6. Morel AP, Lievre M, Thomas C, et al. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS ONE. 2008;3(8):e2888.
7. Gupta PB, Chaffer CL, Weinberg RA. Cancer stem cells: mirage or reality? Nat Med. 2009;15(9):1010-1012.
8. Landgraf P, Rusu M, Sheridan R, et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell. 2007;129(7):1401-1414.
9. Barroso-del Jesus A, Lucena-Aguilar G, Menendez P. The miR- 302-367 cluster as a potential stemness regulator in ESCs. Cell Cycle. 2009;8(3):394-398.
10. Card DA, Hebbar PB, Li L, et al. Oct4/Sox2-regulated miR-302 targets cyclin D1 in human embryonic stem cells. Mol Cell Biol. 2008;28(20):6426-6438.
11. Rosa A, Brivanlou AH. A regulatory circuitry comprised of miR-302 and the transcription factors OCT4 and NR2F2 regulates human embryonic stem cell differentiation. EMBO J. 2011;30(2):237-248.
12. Lin SL, Chang DC, Chang-Lin S, et al. Mir-302 reprograms human skin cancer cells into a pluripotent ES-cell-like state. RNA. 2008;14(10):2115-2124.
13. Barroso-Deljesus A, Lucena-Aguilar G, Sanchez L, et al. The Nodal inhibitor Lefty is negatively modulated by the microRNA miR-302 in human embryonic stem cells. FASEB J. 2011;25(5):1497-1508.
14. Subramanyam D, Lamouille S, Judson RL, et al. Multiple targets of miR-302 and miR-372 promote reprogramming of human fibroblasts to induced pluripotent stem cells. Nat Biotechnol. 2011;29(5):443-448.
15. Nguyen DX, Bos PD, Massague J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer. 2009;9(4):274-284.
16. Liu CG, Calin GA, Volinia S, et al. MicroRNA expression profiling using microarrays. Nat Protoc. 2008;3(4):563-578.
17. Volinia S, Visone R, Galasso M, et al. Identification of microRNA activity by Targets' Reverse EXpression. Bioinformatics. 2010;26(1):91-97.
18. Sridharan R, Tchieu J, Mason MJ, et al. Role of the murine reprogramming factors in the induction of pluripotency. Cell. 2009;136(2):364-377.
19. Kim JB, Sebastiano V, Wu G, et al. Oct4-induced pluripotency in adult neural stem cells. Cell. 2009;136(3):411-419.
20. Yi R, Poy MN, Stoffel M, et al. A skin microRNA promotes differentiation by repressing 'stemness.' Nature. 2008;452(7184):225-229.
21. Gregory PA, Bert AG, Paterson EL, et al. The miR-200 family and miR- 205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol. 2008;10(5):593-601.
22. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer. 2009;9(4):265-273.
23. Baek D, Villen J, Shin C, et al. The impact of microRNAs on protein output. Nature. 2008;455(7209):64-71.
24. Selbach M, Schwanhausser B, Thierfelder N, et al. Widespread changes in protein synthesis induced by microRNAs. Nature. 2008;455(7209):58-63.
25. Palmer RD, Murray MJ, Saini HK, et al. Malignant germ cell tumors display common microRNA profiles resulting in global changes in expression of messenger RNA targets. Cancer Res. 2010;70(7):2911-2923.
26. Murray MJ, Saini HK, van Dongen S, et al. The two most common histological subtypes of malignant germ cell tumour are distinguished by global microRNA profiles, associated with differential transcription factor expression. Mol Cancer. 2010;9:290.
27. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61-70.
28. De Craene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nature Reviews Cancer. 2013;13(2):97-110.
29. Prat A, Parker JS, Karginova O, et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010;12(5):R68.
30. Marotta LL, Almendro V, Marusyk A, et al. The JAK2/STAT3 signaling pathway is required for growth of CD44(+)CD24(-) stem cell-like breast cancer cells in human tumors. J Clin Invest. 2011;121(7):2723-2735.
31. Sheridan C, Kishimoto H, Fuchs RK, et al. CD44+/CD24-breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res. 2006;8(5):R59.
32. Taube JH, Malouf GG, Lu E, et al. Epigenetic silencing of microRNA-203 is required for EMT and cancer stem cell properties. Scientific Reports. 2013;3:2687.
33. Liu S, Dontu G, Mantle ID, et al. Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res. 2006;66(12):6063-6071.
34. Shimono Y, Zabala M, Cho RW, et al. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell. 2009;138(3):592-603.
35. Shipitsin M, Campbell LL, Argani P, et al. Molecular definition of breast tumor heterogeneity. Cancer Cell. 2007;11(3):259-273.
36. Volinia S, Galasso M, Costinean S, et al. Reprogramming of miRNA networks in cancer and leukemia. Genome Res. 2010;20(5):589-599.
37. Adorno M, Cordenonsi M, Montagner M, et al. A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell. 2009;137:87-98.
38. Wellner U, Schubert J, Burk UC, et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol. 2009;11(12):1487-1495.